Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
Status:
Completed
Trial end date:
2021-04-20
Target enrollment:
Participant gender:
Summary
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter
study in participants with mild to moderate plaque psoriasis. The duration of study
participation will be approximately 22 weeks, including up to a 6 week screening period, 12
week treatment period, and approximately 4 week follow up period. Approximately 280
participants are planned to be randomized into the study.